• News

"PTK6 Inhibitors May Target Endocrine Therapy-Resistant ER+ Breast Cancer"

  • Medical Research
  • New York, NY
  • (November 20, 2017)

Interview with Hanna Irie, MD, PhD, senior author and assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai and a medical oncologist at the Dubin Breast Center at The Mount Sinai Hospital answers several questions regarding ER+ breast cancer. Dr. Irie shares, “Additional studies validating PTK6 as a therapeutic target for ER+ breast cancer, the most common breast cancer subtype, are underway and could lead to a novel approach to treating these cancers.”

- Hanna Irie, MD, PhD, Assistant Professor, Medicine, Hematology and Medical Oncology, Oncological Services, Icahn School of Medicine at Mount Sinai, Medical Oncologist, Dubin Breast Center, The Mount Sinai Hospital

Learn more